DSpace Kyoto University
Japanese | English 

Kyoto University Research Information Repository >
Graduate School of Medicine >
Acta Urologica Japonica >
Vol.52 No.10 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/2433/71255

Full text link:

File Description SizeFormat
52_781.pdf3.18 MBAdobe PDFView/Open
Title: 内分泌療法後の前立腺癌組織の検討
Other Titles: Histological investigation of prostate cancer treated with hormonal agents
Authors: 安住, 誠 researcher_resolver
佐賀, 祐司 researcher_resolver
橋本, 博 researcher_resolver
柿崎, 秀宏 researcher_resolver
Author's alias: Azumi, Makoto
Saga, Yuji
Hashimoto, Hiroshi
Kakizaki, Hidehiro
Keywords: Prostate cancer
Hormonal therapy
Cytokeratin
Issue Date: Oct-2006
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 52
Issue: 10
Start page: 781
End page: 784
Abstract: 1994年7月~2005年2月に3ヵ月以上の内分泌療法後に前立腺前摘除術を行い、pT0と診断された11例を対象とした。内分泌療法はLH-RHアナログ単独投与または抗アンドロゲン剤と併用投与が行われていた。病理学的に残存癌を認めない11例中9例は、サイトケラチン染色でも癌病巣は確認できなかったが、2例に残存癌が検出された(症例2と症例7)を報告した。症例2(64歳男)。1997年9月にPSA8.1ng/mlで経直腸的前立腺生検を実施し、低分化型腺癌診断のもとMAB療法を4ヵ月間実施後、翌年2月に根治的前立腺全摘除術を行った。残存癌なしで経過観察中、H-E染色で認識しにくい小腺管構造がAE1/AE3染色で多数確認された。症例7(58歳男)。2003年3月にPSA10.5ng/mlで経直腸的前立腺生検を実施し、中分化型腺癌と診断されMAB療法を5ヵ月実施した。半年後に根治的前立腺前摘除術後、残存癌なしで経過観察中、H-E染色で認識しにくい小腺管構造がAE1/AE3染色で多数確認された。
The histological diagnosis of prostate cancer treated with hormonal agents is often difficult because of various morphological changes induced by androgen ablation. Immunostaining of cytokeratins may be useful to prevent the underdetection of cancer cells. We examined prostatic specimens with histological diagnosis of 11 pTO patients who had undergone neoadjuvant endocrine therapy followed by radical prostatectomy. Anti-cytokeratin antibody, AE1/AE3 was used to detect the prostatic epithelial cells. Anti-cytokeratin antibody, 34/3 E12 was used to detect the prostatic basal cells. The loss of basal cells indicates the acini to be cancer. The immunostaining with these antibodies revealed that 2 out of 11 cases had residual cancer and were not pTO. The immunostaining of cytokeratins was useful to detect the residual prostatic cancer after endocrine therapy.
URI: http://hdl.handle.net/2433/71255
PubMed ID: 17131867
Appears in Collections:Vol.52 No.10


Export to RefWorks

Access count of this item: 143

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Feedback - Privacy policy